<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00441974</url>
  </required_header>
  <id_info>
    <org_study_id>ADF108356</org_study_id>
    <nct_id>NCT00441974</nct_id>
  </id_info>
  <brief_title>Adefovir Dipivoxil For The Treatment Of Chinese Compensated Chronic Hepatitis B(CHB)Patients</brief_title>
  <official_title>A 48-week Multi-centre, Open-label, Local Phase IV Study to Demonstrate the Efficacy and Safety of Adefovir Dipivoxil Tablets (10mg) in Chinese Subjects With Compensated Chronic Hepatitis B</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      This 48-week open-label study of local manufactured adefovir dipivoxil Tablet evaluates the
      efficacy and safety of adefovir 10mg once daily in Chinese subjects with compensated CHB.
      Primary endpoint is proportion of subjects achieving HBV DNA undetectable (&lt;=1000 copies/mL
      by by Roche COBAS AMPLICOR HBV MONITOR Test) at week 48. Approximately 1250 patients will be
      recruited in 30 study centers in China. The subjects are offered 48 weeks of open label
      adefovir dipivoxil treatment, with assessments every three months, after with is a 12-week
      post study treatment follow-up prior to study completion.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Achieving HBV DNA (Hepatitis B Virus Deoxyribonucleic Acid) &lt;1000 Copies/Milliliter at Week 48</measure>
    <time_frame>Week 48</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of HBeAg Positive Participants Achieving Histological Improvement at Week 48</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ranked Assessment of Liver Histology in HBeAg Positive Participants From Baseline to Week 48</measure>
    <time_frame>Baseline to Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Screening in Median Serum HBV DNA at Weeks 24 and 48</measure>
    <time_frame>Weeks 24 and 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Achieving ALT (Alanine Aminotransferase) Normalization at Week 48</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of HBeAg Positive Participants Achieving HBeAg Loss and HBeAg Seroconversion at Week 48</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With ADV-associated Resistance at Week 48</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1470</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Single arm adefovir dipivoxil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>adefovir dipivoxil once daily orally 10 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>adefovir dipivoxil</intervention_name>
    <description>adefovir dipivoxil once daily one tablet 10mg orally</description>
    <arm_group_label>Single arm adefovir dipivoxil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects aged 18-65 years inclusive

          -  Documented chronic hepatitis B infection determined by the presence of serum HBsAg for
             a least 6 months

          -  Serum HBV DNA ≥105 copies/ml for HBeAg positive subjects or ≥104 copies/ml for HBeAg
             negative subjects (Real-time PCR, LLQ=1000cp/ml) at study screening (within 2 weeks
             before baseline), respectively.

          -  ALT value ≥2 times the upper limit of normal (ULN) at the time of screening, as
             determined using laboratory ranges and documented ALT abnormal within 6 month prior
             the study screening.

          -  Compensated liver disease with the following laboratory and clinical parameters study
             screening:

          -  prothrombin time ≤ 2 seconds above normal direct bilirubin

          -  Albumin≥35g/L

          -  Total bilirubin ≤2.5mg/dL (≤ 43 µmol/L) or normal direct bilirubin

          -  No history of variceal bleeding

          -  No history of encephalopathy

          -  No history of ascites

          -  Willing and able to undergo two liver biopsies (prior to dosing, and after 48 weeks of
             therapy; only apply to subjects who are enrolled to the sites where liver biopsy is
             required).

          -  Agree not to participate in any other investigational trials or to undertake other HBV
             systemic antiviral regimens during participation in this study

        Exclusion Criteria:

        A subject will not be eligible for inclusion in this study if any of the following criteria
        apply:

          -  Any serious or active medical or psychiatric illnesses other than hepatitis B which,
             in the opinion of the investigator, would interfere with patient treatment, assessment
             or compliance with the protocol. This would include, may not limit to, renal, cardiac,
             pulmonary, vascular, neurogenic, digestive, metabolic (diabetes, thyroid disorders,
             adrenal disease), immunodeficiency disorders, active infection or cancer.

          -  Documented evidence of active liver disease due to other causes including

          -  co-infection hepatitis C (HCV), Subjects who are anti-HCV positive and in whom HCV RNA
             is undetectable are considered to be HCV seropositive and will not be eligible

          -  co-infection with hepatitis delta (HDV)

          -  co-infection with HIV

          -  autoimmune hepatitis (antinuclear antibody titre&gt;1:160)

          -  Alanine aminotransferase(ALT) &gt; 10 times ULN at screening or history of acute
             exacerbation leading to transient decompensation

          -  Serum alpha fetoprotein (AFP) &gt;50 ng/mL.

          -  Hepatocellular carcinoma as evidenced by one of the following:

          -  suspicious foci on ultrasound or radiological examination

          -  where no positive ultrasound finding, but serum alpha-fetoprotein &gt; 100ng/ml

          -  Adequate renal function defined as serum creatinine &gt;1.5 mg/dL (&gt;130 µmol/L)

          -  Adequate hematological function defined as:

          -  Absolute neutrophil count &lt;1 x 10³/mm³ (1 x 10^9/L)

          -  Platelets&lt;80 x 10³/mm³ (80 x 10^9/L); platelets&lt;100 x 10³/mm³ (100 x 10^9/L)

          -  Hemoglobin&lt;12g/dL (120 g/L)(males) or &lt;10 g/dL (100 g/L) (females)

          -  Active alcohol or drug abuse or history of alcohol or drug abuse considered by the
             investigator to be sufficient to hinder compliance with treatment, participation in
             the study or interpretation of results.

          -  Use of immunosuppressive therapy, immunomodulatory therapy (including interferon or
             thymosin), systemic cytotoxic agents within the previous 6 months or during the study.

          -  Use of chronic anti-viral agents(e.g. lamivudine, adefovir dipivoxil, entecavir,
             famciclovir, tenofovir, FTC, ganciclovir, DAPD, LfMA, HBIg, etc.), Chinese herbal
             medicines known to have activity against HBV within the previous 3 months or during
             the study; use of agents with effect of ALT reduction (e.g. schisandra agents) during
             the study.

          -  Received nephrotoxic drugs (e.g., aminoglycosides, amphotericin B, vancomycin,
             cidofovir, foscarnet, cis-platinum, pentamidine etc.) or competitors of renal
             excretion (e.g., probenecid within 2 months prior to study screening or the
             expectation that patient will receive any of these during the course of the study.

          -  Received hepatotoxic drugs (e.g., anabolic steroids, ketaconazole, itraconazole,
             isoniazid, rifampin, rifabutin) within 2 months prior to study screening or expected
             to receive these during the course of the study.

          -  Previous (or planned) participation in an investigational trial involving
             administration of investigational compound within 2 months prior to the study
             screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510630</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210002</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Beijing</city>
        <zip>100011</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Beijing</city>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Beijing</city>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Beijing</city>
        <zip>100069</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Changsha</city>
        <zip>410008</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Changsha</city>
        <zip>410011</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chongqing</city>
        <zip>400038</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chongquin</city>
        <zip>400038</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fuzhou</city>
        <zip>350025</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jinan</city>
        <zip>250021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tianjin</city>
        <zip>300192</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 28, 2007</study_first_submitted>
  <study_first_submitted_qc>February 28, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 1, 2007</study_first_posted>
  <results_first_submitted>August 26, 2009</results_first_submitted>
  <results_first_submitted_qc>August 26, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 2, 2009</results_first_posted>
  <last_update_submitted>October 15, 2009</last_update_submitted>
  <last_update_submitted_qc>October 15, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 20, 2009</last_update_posted>
  <responsible_party>
    <name_title>Study Director</name_title>
    <organization>GSK</organization>
  </responsible_party>
  <keyword>adefovir dipivoxil</keyword>
  <keyword>compensated</keyword>
  <keyword>chronic hepatitis B</keyword>
  <keyword>Chinese</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adefovir</mesh_term>
    <mesh_term>Adefovir dipivoxil</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>10 mg Adefovir Dipivoxil</title>
          <description>Adefovir Dipivoxil (ADV) 10 mg tablets once daily for 48 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1470"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1342"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="128"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Consent Withdrawn</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="80"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>10 mg Adefovir Dipivoxil</title>
          <description>Adefovir Dipivoxil (ADV) 10 mg tablets once daily for 48 weeks</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1467"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>The Intent-to-Treat (ITT) Population was used as the analysis population.</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.5" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>The Intent-to-Treat (ITT) Population was used as the analysis population.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="291"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <description>The Intent-to-Treat (ITT) Population was used as the analysis population.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1467"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Achieving HBV DNA (Hepatitis B Virus Deoxyribonucleic Acid) &lt;1000 Copies/Milliliter at Week 48</title>
        <description>HBV (Hepatitis B Virus) DNA level was tested by real-time Polymerase Chain Reaction at Week 48.</description>
        <time_frame>Week 48</time_frame>
        <population>Intent-to-Treat (ITT) Population: all participants who actually received the study medication at least once.</population>
        <group_list>
          <group group_id="O1">
            <title>HBeAg+ at Baseline</title>
            <description>Participants who had detectable HBeAg (Hepatitis B e Antigens) as measured by a local laboratory</description>
          </group>
          <group group_id="O2">
            <title>HBeAg- at Baseline</title>
            <description>Participants who had undetectable HBeAg as measured by a local laboratory</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>Total of HBeAg+ and HBeAg- participants</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Achieving HBV DNA (Hepatitis B Virus Deoxyribonucleic Acid) &lt;1000 Copies/Milliliter at Week 48</title>
          <description>HBV (Hepatitis B Virus) DNA level was tested by real-time Polymerase Chain Reaction at Week 48.</description>
          <population>Intent-to-Treat (ITT) Population: all participants who actually received the study medication at least once.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1108"/>
                <count group_id="O2" value="359"/>
                <count group_id="O3" value="1467"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HBV DNA &lt;1000 copies (cp)/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="341"/>
                    <measurement group_id="O2" value="243"/>
                    <measurement group_id="O3" value="584"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBV DNA &gt;1000 cp/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="767"/>
                    <measurement group_id="O2" value="116"/>
                    <measurement group_id="O3" value="883"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of HBeAg Positive Participants Achieving Histological Improvement at Week 48</title>
        <description>Histological improvement (defined as a ≥2 point reduction in the Knodell necroinflammation score without worsening fibrosis) was accessed by two pathologists in HBeAg-positive participants undergoing liver biopsy at baseline and week 48/withdrawal. Knodell/Histological Activity Index (HAI) score = combined scores for necrosis, inflammation, and fibrosis and is the sum of scores for periportal bridging necrosis (0–10: none=0, multilobular necrosis=10), intralobular degeneration and focal necrosis and portal inflammation (0–4: none=0, marked=4), and fibrosis (0–4: none=0, cirrhosis=4).</description>
        <time_frame>Week 48</time_frame>
        <population>HBeAg positive chronic hepatitis B participants who underwent liver biopsy at Week 48</population>
        <group_list>
          <group group_id="O1">
            <title>HBeAg+ at Baseline</title>
            <description>Participants who had detectable HBeAg (Hepatitis B e Antigens) as measured by a local laboratory</description>
          </group>
        </group_list>
        <measure>
          <title>Number of HBeAg Positive Participants Achieving Histological Improvement at Week 48</title>
          <description>Histological improvement (defined as a ≥2 point reduction in the Knodell necroinflammation score without worsening fibrosis) was accessed by two pathologists in HBeAg-positive participants undergoing liver biopsy at baseline and week 48/withdrawal. Knodell/Histological Activity Index (HAI) score = combined scores for necrosis, inflammation, and fibrosis and is the sum of scores for periportal bridging necrosis (0–10: none=0, multilobular necrosis=10), intralobular degeneration and focal necrosis and portal inflammation (0–4: none=0, marked=4), and fibrosis (0–4: none=0, cirrhosis=4).</description>
          <population>HBeAg positive chronic hepatitis B participants who underwent liver biopsy at Week 48</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Histological improvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No histological improvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ranked Assessment of Liver Histology in HBeAg Positive Participants From Baseline to Week 48</title>
        <description>A ranked assessment with the Knodell/HAI scoring system that represents the sum of scores for periportal bridging necrosis (0–10: none=0, moderate piecemeal necrosis plus bridging necrosis=5, multilobular necrosis=10); interlobular degeneration and focal necrosis (0–4: none=0, marked=4); portal inflammation (0–4: none=0, marked=4) and fibrosis (0–4: none=0, fibrous portal expansion=1, bridging fibrosis=3, cirrhosis=4) was carried out by two pathologists in the HBeAg positive participants who underwent liver biopsy at baseline and Week 48/withdrawal.</description>
        <time_frame>Baseline to Week 48</time_frame>
        <population>HBeAg positive chronic hepatitis B participants who underwent liver biopsy at Week 48</population>
        <group_list>
          <group group_id="O1">
            <title>HBeAg+ at Baseline</title>
            <description>Participants who had detectable HBeAg (Hepatitis B e Antigens) as measured by a local laboratory</description>
          </group>
        </group_list>
        <measure>
          <title>Ranked Assessment of Liver Histology in HBeAg Positive Participants From Baseline to Week 48</title>
          <description>A ranked assessment with the Knodell/HAI scoring system that represents the sum of scores for periportal bridging necrosis (0–10: none=0, moderate piecemeal necrosis plus bridging necrosis=5, multilobular necrosis=10); interlobular degeneration and focal necrosis (0–4: none=0, marked=4); portal inflammation (0–4: none=0, marked=4) and fibrosis (0–4: none=0, fibrous portal expansion=1, bridging fibrosis=3, cirrhosis=4) was carried out by two pathologists in the HBeAg positive participants who underwent liver biopsy at baseline and Week 48/withdrawal.</description>
          <population>HBeAg positive chronic hepatitis B participants who underwent liver biopsy at Week 48</population>
          <units>points on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Knodell score at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Knodell score at Week 48/withdrawal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Necroinflammation score at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Necroinflammation score at Week 48/withdrawal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fibrosis score at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fibrosis score at Week 48/withdrawal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Screening in Median Serum HBV DNA at Weeks 24 and 48</title>
        <description>The HBV DNA level was tested in blood serum by real-time Polymerase Chain Reaction with the LLD (lower limit of detection) as 300 copies/milliliter (cp/mL) at screening, week 24, and week 48 in a central laboratory. The change in HBV DNA from screening to week 24 and week 48 was conducted.</description>
        <time_frame>Weeks 24 and 48</time_frame>
        <population>Intent-to-Treat (ITT) Population: all participants who actually received the study medication at least once.</population>
        <group_list>
          <group group_id="O1">
            <title>HBeAg+ at Baseline</title>
            <description>Participants who had detectable HBeAg (Hepatitis B e Antigens) as measured by a local laboratory</description>
          </group>
          <group group_id="O2">
            <title>HBeAg- at Baseline</title>
            <description>Participants who had undetectable HBeAg as measured by a local laboratory</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Screening in Median Serum HBV DNA at Weeks 24 and 48</title>
          <description>The HBV DNA level was tested in blood serum by real-time Polymerase Chain Reaction with the LLD (lower limit of detection) as 300 copies/milliliter (cp/mL) at screening, week 24, and week 48 in a central laboratory. The change in HBV DNA from screening to week 24 and week 48 was conducted.</description>
          <population>Intent-to-Treat (ITT) Population: all participants who actually received the study medication at least once.</population>
          <units>log10 copies/milliliter</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1108"/>
                <count group_id="O2" value="359"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serum HBV DNA Change at Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.1" lower_limit="-9.4" upper_limit="2.8"/>
                    <measurement group_id="O2" value="-4.3" lower_limit="-9.0" upper_limit="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum HBV DNA Change at Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.6" lower_limit="-9.4" upper_limit="3.5"/>
                    <measurement group_id="O2" value="-4.6" lower_limit="-9.0" upper_limit="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Achieving ALT (Alanine Aminotransferase) Normalization at Week 48</title>
        <description>Elevated serum ALT levels are defined as serum ALT levels greater than the upper limit of the normal range (ULN), as determined using local laboratory ranges. ALT normalization was defined as ALT measurements at or below the ULN after a baseline value above the ULN.</description>
        <time_frame>Week 48</time_frame>
        <population>Intent-to-Treat (ITT) Population: all participants who actually received the study medication at least once.</population>
        <group_list>
          <group group_id="O1">
            <title>HBeAg+ at Baseline</title>
            <description>Participants who had detectable HBeAg (Hepatitis B e Antigens) as measured by a local laboratory</description>
          </group>
          <group group_id="O2">
            <title>HBeAg- at Baseline</title>
            <description>Participants who had undetectable HBeAg as measured by a local laboratory</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Achieving ALT (Alanine Aminotransferase) Normalization at Week 48</title>
          <description>Elevated serum ALT levels are defined as serum ALT levels greater than the upper limit of the normal range (ULN), as determined using local laboratory ranges. ALT normalization was defined as ALT measurements at or below the ULN after a baseline value above the ULN.</description>
          <population>Intent-to-Treat (ITT) Population: all participants who actually received the study medication at least once.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1108"/>
                <count group_id="O2" value="359"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ALT normalization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="780"/>
                    <measurement group_id="O2" value="258"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT non-normalization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="328"/>
                    <measurement group_id="O2" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of HBeAg Positive Participants Achieving HBeAg Loss and HBeAg Seroconversion at Week 48</title>
        <description>HBeAg loss and HBeAg seroconversion (HBeAg loss and HBeAb detected) were assessed in participants who were HBeAg positive at Weeks 0 and 48. Confirmed HBeAg loss was defined as undetectable HBeAg.</description>
        <time_frame>Week 48</time_frame>
        <population>Intent-to-Treat (ITT) Population: all HBeAg positive participants who actually received the study medication at least once</population>
        <group_list>
          <group group_id="O1">
            <title>HBeAg+ at Baseline</title>
            <description>Participants who had detectable HBeAg (Hepatitis B e Antigens) as measured by a local laboratory</description>
          </group>
        </group_list>
        <measure>
          <title>Number of HBeAg Positive Participants Achieving HBeAg Loss and HBeAg Seroconversion at Week 48</title>
          <description>HBeAg loss and HBeAg seroconversion (HBeAg loss and HBeAb detected) were assessed in participants who were HBeAg positive at Weeks 0 and 48. Confirmed HBeAg loss was defined as undetectable HBeAg.</description>
          <population>Intent-to-Treat (ITT) Population: all HBeAg positive participants who actually received the study medication at least once</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HBeAg loss</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="289"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBeAg seroconversion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With ADV-associated Resistance at Week 48</title>
        <description>Week 48 serum samples from participants, who reached a HBV DNA breakthrough or have HBV DNA≥5 log copies/mL at Weeks 24 and 48 were assessed for the development of ADV (Adefovir dipivoxil) mutation (N236T and A181V) in the HBV polymerase. Virologic breakthrough was defined as an increase in the level of HBV DNA 1 log10 copy/mL from Week 24 to Week 48. ADV-associated resistance was defined as participants with both virologic breakthrough and ADV mutation.</description>
        <time_frame>Week 48</time_frame>
        <population>Intent-to-Treat (ITT) Population: all participants who actually received the study medication at least once.</population>
        <group_list>
          <group group_id="O1">
            <title>10 mg Adefovir Dipivoxil</title>
            <description>Adefovir Dipivoxil (ADV) 10 mg tablets once daily for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With ADV-associated Resistance at Week 48</title>
          <description>Week 48 serum samples from participants, who reached a HBV DNA breakthrough or have HBV DNA≥5 log copies/mL at Weeks 24 and 48 were assessed for the development of ADV (Adefovir dipivoxil) mutation (N236T and A181V) in the HBV polymerase. Virologic breakthrough was defined as an increase in the level of HBV DNA 1 log10 copy/mL from Week 24 to Week 48. ADV-associated resistance was defined as participants with both virologic breakthrough and ADV mutation.</description>
          <population>Intent-to-Treat (ITT) Population: all participants who actually received the study medication at least once.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1467"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HBV DNA breakthrough</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ADV-associated resistance</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBV DNA≥5 log copies/ml at Weeks 24 and 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="322"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>10 mg Adefovir Dipivoxil</title>
          <description>Adefovir Dipivoxil (ADV) 10 mg tablets once daily for 48 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1467"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Hepatitis B</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1467"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1467"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1467"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1467"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Hepatic neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1467"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1467"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1467"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1467"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="86" subjects_at_risk="1467"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

